SevenBridge Financial Group LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

SevenBridge Financial Group LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 1.1% during the third quarter, Holdings Channel reports. The institutional investor owned 45,989 shares of the company’s stock after purchasing an additional 484 shares during the quarter. Johnson & Johnson comprises approximately 2.5% of SevenBridge Financial Group LLC’s portfolio, making the stock its 6th largest holding. SevenBridge Financial Group LLC’s holdings in Johnson & Johnson were worth $7,427,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in JNJ. Newton One Investments LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $32,000. Robbins Farley LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $33,000. Lion Street Advisors LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $36,000. Finally, Alpha Paradigm Partners LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $47,000. 67.14% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently issued reports on the company. SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, July 29th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price target for the company in a research note on Friday, October 22nd. Wells Fargo & Company reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, October 7th. Morgan Stanley downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price for the company. in a research report on Tuesday, September 7th. Finally, Raymond James cut their target price on Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, October 20th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $187.78.

Shares of JNJ opened at $160.24 on Thursday. Johnson & Johnson has a 12-month low of $142.86 and a 12-month high of $179.92. The business has a 50-day simple moving average of $162.64 and a two-hundred day simple moving average of $167.35. The company has a quick ratio of 1.11, a current ratio of 1.34 and a debt-to-equity ratio of 0.43. The stock has a market cap of $421.85 billion, a PE ratio of 23.95, a PEG ratio of 2.38 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Monday, October 18th. The company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.35 by $0.25. The company had revenue of $23.34 billion during the quarter, compared to analysts’ expectations of $23.72 billion. Johnson & Johnson had a return on equity of 37.90% and a net margin of 19.55%. The business’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.20 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 9.78 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 7th. Stockholders of record on Tuesday, November 23rd will be paid a $1.06 dividend. The ex-dividend date of this dividend is Monday, November 22nd. This represents a $4.24 annualized dividend and a dividend yield of 2.65%. Johnson & Johnson’s payout ratio is 63.38%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.